RJA
TXMD icon

Raymond James & Associates’s TherapeuticsMD TXMD Stock Holding History

Raymond James & Associates’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,216
Closed -$15K – 3693
2018
Q3 		$15K Buy
+1,216
New +$373K ﹤0.01% 3561
2018
Q2 		– Sell
-300
Closed -$6K – 3674
2018
Q1 		$6K Sell
300
-1,260
-81% -$353K ﹤0.01% 3424
2017
Q4 		$34K Buy
+1,560
New +$434K ﹤0.01% 3313

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Raymond James & Associates's TXMD Position: Q2 2022 in Review

Raymond James & Associates sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 1,455 shares — an estimated $28K sold.

Raymond James & Associates first reported a position in TXMD in Q1 2015 and held it in 28 quarters. The position peaked at $4.97M in Q3 2018. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

  • Raymond James & Associates reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
  • Raymond James & Associates sold 1,455 TherapeuticsMD shares in Q2 2022, an estimated $28K.
  • Raymond James & Associates first reported a position in TherapeuticsMD in Q1 2015 and held it in 28 quarters.
  • Raymond James & Associates's TherapeuticsMD position peaked at $4.97M in Q3 2018.
  • 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Raymond James & Associates's 13F filing for Q2 2022, filed 12 Aug 2022.